Agilent opens new lab facility in Bangalore, India

Agilent Technologies Inc. (NYSE:A) has expanded its Life Sciences and Chemical Analysis Center of Excellence in Bangalore. The company also has opened a Life Science application development lab, in an adjacent facility, to accelerate the discovery of life science analysis workflows. Together, the center and lab cover 8,000 square feet, making this the largest Agilent research facility in the world.

"India continues to be one of the most important markets for Agilent globally, with a significant presence of high-end R&D in pharmaceuticals and biotechnology," said Parmeet Ahuja, Country General Manager, Agilent Technologies, India. "This is the first Agilent lab facility where development of application solutions, customer interactions and training will happen in parallel."

Originally opened in 2006, the Bangalore center serves Agilent's customers across India. Customers now have access to Agilent's newest high-end products, including the 7700 Series ICP-MS, 7000B GC-QQQ, 6490 QQQ, 6540 QTOF and the Agilent 1290 and 1260 Infinity LC. Additionally, all of Agilent's core products, including gas chromatographs, liquid chromatographs, electrophoresis and genomics products, and mass spectrometry systems are available for use. Customers and collaborators can use the center to evaluate how Agilent products perform with their types of samples and applications.

The combined facility plays an important role not just in applications and solutions development, but also in customer education. Agilent application scientists engaged in pharma, biopharma and other life science applications staff the facility and work hand in hand with customers, thereby having access to critical samples and learning about emerging application needs.

The Bangalore Center of Excellence is modeled on the same standards as other Agilent centers, with an emphasis on Agilent's global environmental, health and safety guidelines.

Source: Agilent Technologies

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
At-home antibody tests could drive higher COVID-19 booster rates, new research finds